Nalmefene Hydrochloride Patent Expiration

Nalmefene Hydrochloride is Used for reversing opioid overdose. It was first introduced by Hikma Pharmaceuticals Usa Inc in its drug Revex on Apr 17, 1995. Another drug containing Nalmefene Hydrochloride is Opvee. 4 different companies have introduced drugs containing Nalmefene Hydrochloride.


Nalmefene Hydrochloride Patents

Given below is the list of patents protecting Nalmefene Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Opvee US11458091 Compositions and methods for the treatment of opioid overdose Jul 10, 2038 Indivior


Coming Soon

Patent Strength Analyzer

Let us know if you're excited!

🤩🥱

Thank you for your response 🥳

Nalmefene Hydrochloride Generics

Several generic applications have been filed for Nalmefene Hydrochloride. The first generic version for Nalmefene Hydrochloride was by Purdue Pharma Lp and was approved on Feb 8, 2022. And the latest generic version is by Chengdu Shuode Pharmaceutical Co Ltd and was approved on Nov 15, 2023.

Given below is the list of companies who have filed for Nalmefene Hydrochloride generic.


1. CHENGDU SHUODE

Chengdu Shuode Pharmaceutical Co Ltd has filed for 2 different strengths of generic version for Nalmefene Hydrochloride. Given below are the details of the strengths of this generic introduced by Chengdu Shuode.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) solution Discontinued INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS N/A Nov 15, 2023
EQ 2MG BASE/2ML (EQ 1MG BASE/ML) solution Discontinued INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS N/A Nov 15, 2023


2. PURDUE PHARMA LP

Purdue Pharma Lp has filed for 1 generic for Nalmefene Hydrochloride. Given below are the details of the strengths of this generic introduced by Purdue Pharma Lp.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

(reference standard)

solution Prescription INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS N/A Feb 8, 2022